laitimes

Watson Bioteloent Flow Brain Conjugate Vaccine entered Phase III clinical trials

author:Beijing News

Beijing News (reporter Zhang Xiulan) on October 12, Watson Biology announced that the ACYW135 meningococcal polysaccharide conjugate vaccine (hereinafter referred to as the quadrivalent flow brain conjugate vaccine) independently developed by the company and its subsidiary Yuxi Watson Biotechnology Co., Ltd. recently received an ethical review opinion issued by the Guangxi Ethics Review Committee to carry out phase III clinical trials, and the vaccine entered the phase III clinical trial stage.

The vaccine is a prophylactic biologic and is suitable for the prevention of meningococcal diseases such as meningococcal diseases such as meningococcal epidemic caused by meningococcal infection in groups A, C, Y and W135 in infants and older. Watson Bioteent Quadrivalent Flow Brain Conjugate Vaccine was declared for clinical research in September 2012, and was approved by the Drug Clinical Trial In January 2015, and began to enter the clinical research stage. This vaccine needs to further complete the Phase III clinical trial, and after obtaining the clinical summary report proving the safety and efficacy of the vaccine, it will apply to the State Drug Administration for production approval, and only after obtaining the production approval can it be put into production.

At the market level, at present, the global manufacturers of quadrivalent flow brain conjugate vaccine include Sanofi-Pasteur, GSK and Pfizer, and no local enterprises in China have the production and listing of this product.

In the field of brain flow vaccines, Watson Bio has held 3 products (including group A group C meningococcal polysaccharide vaccine, group A C meningococcal polysaccharide conjugate vaccine and AYW135 group meningococcal polysaccharide vaccine) on the market. Watson Bio said that after obtaining the ethics review opinion of the phase III clinical trial of the quadrivalent flow brain conjugate vaccine, it will promote the phase III clinical trial of the vaccine as soon as possible and strive for the early listing of the product.

Proofreading Wang Xin

Read on